{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T12:48:24Z","timestamp":1776602904115,"version":"3.51.2"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"crossref","award":["112102310306"],"award-info":[{"award-number":["112102310306"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"crossref","award":["112102310306"],"award-info":[{"award-number":["112102310306"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Bureau of Kaifeng","award":["119"],"award-info":[{"award-number":["119"]}]},{"name":"Science and Technology Bureau of Kaifeng","award":["119"],"award-info":[{"award-number":["119"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>A large number of people with Crohn's disease (CD) fail to recover from conventional therapy or biological therapy. Some studies showed that adalimumab (ADA) may be an effective alternative therapy for these patients. The aim of this study was to evaluate the efficacy and safety of ADA in inducing CD remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed search of Pubmed\/MEDLINE, Embase, CENTRAL, the Cochrane IBD Group Specialized Register, and several other databases. Randomized controlled trials (RCTs) comparing any dose of ADA with controls (placebo or active) in participants with active CD were included. The primary outcome was the failure to achieve clinical response\/remission at 4\u00a0weeks. Several subgroup and sensitivity analyses were performed. Review Manager Software v5.3 was used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four RCTs were included (<jats:italic>n<\/jats:italic>\u2009=\u2009919), in which 553 participants received ADA and 366 participants received placebo. A meta-analysis of four studies showed that at 4\u00a0weeks, there were more people in the ADA group with clinical response\/remission or symptom improvement compared with the placebo group. The rates of side effects, serious side effects, and study withdrawals due to side effects were lower in ADA participants than placebo ones.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This meta-analysis shows that ADA is superior to placebo in induction of clinical response\/remission of CD patients, but no firm conclusions can be drawn on the safety of ADA in CD due to the low number of events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s40001-022-00817-6","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T23:04:02Z","timestamp":1664492642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Juntao","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"817_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/s01406736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380:1590\u2013605. https:\/\/doi.org\/10.1016\/s01406736(12)60026-9.","journal-title":"Lancet"},{"key":"817_CR2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.mayocp.2017.04.010","volume":"92","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Cheifetz AS. Crohn Disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92:1088\u2013103. https:\/\/doi.org\/10.1016\/j.mayocp.2017.04.010.","journal-title":"Mayo Clin Proc"},{"key":"817_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","volume":"152","author":"GG Kaplan","year":"2017","unstructured":"Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152:313-21.e2. https:\/\/doi.org\/10.1053\/j.gastro.2016.10.020.","journal-title":"Gastroenterology"},{"key":"817_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000499767","volume":"27","author":"M Sousa","year":"2020","unstructured":"Sousa M, Proen\u00e7a L, Carlos Silva J, Ribeiro Gomes AC, Afeto E, Carvalho J. Duodenal Crohn\u2019s disease complicated by pancreatitis and common bile duct obstruction. GE Port J Gastroenterol. 2020;27:33\u20136. https:\/\/doi.org\/10.1159\/000499767.","journal-title":"GE Port J Gastroenterol"},{"key":"817_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000332079","volume":"85","author":"A Lahat","year":"2012","unstructured":"Lahat A, Lang A, Ben-Horin S. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion. 2012;85:1\u20138. https:\/\/doi.org\/10.1159\/000332079.","journal-title":"Digestion"},{"key":"817_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2036.2004.1873.x","volume":"19","author":"GP Rubin","year":"2004","unstructured":"Rubin GP, Hungin AP, Chinn DJ, Dwarakanath D. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther. 2004;19:529\u201335. https:\/\/doi.org\/10.1111\/j.1365-2036.2004.1873.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"817_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3748\/wjg.v18.i15.1723","volume":"18","author":"\u00d8 Hovde","year":"2012","unstructured":"Hovde \u00d8, Moum BA. Epidemiology and clinical course of Crohn\u2019s disease: results from observational studies. World J Gastroenterol. 2012;18:1723\u201331. https:\/\/doi.org\/10.3748\/wjg.v18.i15.1723.","journal-title":"World J Gastroenterol"},{"key":"817_CR8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1248\/bpb.b18-00261","volume":"41","author":"J Liu","year":"2018","unstructured":"Liu J, Wang H, Li Y, Shi P, Gong J, Gu L, Zhu W, Li J. Anti-mouse CD52 treatment ameliorates colitis through suppressing Th1\/17 mediated inflammation and promoting tregs differentiation in IL-10 deficient mice. Biol Pharm Bull. 2018;41:1423\u20139. https:\/\/doi.org\/10.1248\/bpb.b18-00261.","journal-title":"Biol Pharm Bull"},{"key":"817_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1248\/bpb.b19-00786","volume":"43","author":"J Wang","year":"2020","unstructured":"Wang J, Zhang Z, Fang A, Wu K, Chen X, Wang G, Mao F. Resveratrol attenuates inflammatory bowel disease in mice by regulating SUMO1. Biol Pharm Bull. 2020;43:450\u20137. https:\/\/doi.org\/10.1248\/bpb.b19-00786.","journal-title":"Biol Pharm Bull"},{"key":"817_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.09.21259804","author":"JK Nowak","year":"2021","unstructured":"Nowak JK, Kalla R, Adams AT, Halfvarson J, Satsangi J, Consortium, IB-C. Discovery of a simple two-gene expression biomarker in whole blood predictive of the need for treatment escalation in inflammatory bowel disease. MedRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.07.09.21259804.","journal-title":"MedRxiv"},{"key":"817_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ajg.2008.168","volume":"104","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2009;104:465\u201383. https:\/\/doi.org\/10.1038\/ajg.2008.168.","journal-title":"Am J Gastroenterol"},{"key":"817_CR12","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/apt.16057","volume":"52","author":"T Townsend","year":"2020","unstructured":"Townsend T, Razanskaite V, Dodd S, Storey D, Michail S, Morgan J, Davies M, Penman D, Watters C, Swaminathan M, Sabine J, Chapman A, Smith PJ, Flanagan PK, Reilly I, Bodger K, Subramanian S. Comparative effectiveness of ustekinumab or vedolizumab after 1\u00a0year in 130 patients with anti-TNF-refractory Crohn\u2019s disease. Aliment Pharmacol Ther. 2020;52:1341\u201352. https:\/\/doi.org\/10.1111\/apt.16057.","journal-title":"Aliment Pharmacol Ther"},{"key":"817_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/apt.14794","volume":"48","author":"WJ Sandborn","year":"2018","unstructured":"Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG. Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48:65\u201377. https:\/\/doi.org\/10.1111\/apt.14794.","journal-title":"Aliment Pharmacol Ther"},{"key":"817_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10620-018-4917-7","volume":"63","author":"K Papamichael","year":"2018","unstructured":"Papamichael K, Vajravelu RK, Osterman MT, Cheifetz AS. Long-term outcome of infliximab optimization for overcoming immunogenicity in patients with inflammatory bowel disease. Dig Dis Sci. 2018;63:761\u20137. https:\/\/doi.org\/10.1007\/s10620-018-4917-7.","journal-title":"Dig Dis Sci"},{"key":"817_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2147\/btt.s3292","volume":"2","author":"A Cassinotti","year":"2008","unstructured":"Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn\u2019s disease. Biologics. 2008;2:763\u201377. https:\/\/doi.org\/10.2147\/btt.s3292.","journal-title":"Biologics"},{"key":"817_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s Disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3\u201325. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw168.","journal-title":"J Crohns Colitis"},{"key":"817_CR17","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.18902.1","author":"M Samaan","year":"2019","unstructured":"Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn\u2019s disease: optimising the old and maximising the new. F1000Res. 2019. https:\/\/doi.org\/10.12688\/f1000research.18902.1.","journal-title":"F1000Res"},{"key":"817_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323\u201333. https:\/\/doi.org\/10.1053\/j.gastro.2005.11.030.","journal-title":"Gastroenterology."},{"key":"817_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","volume":"148","author":"GS Hazlewood","year":"2015","unstructured":"Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, Kuenzig E, Tomlinson G, Siegel CA, Melmed GY, Kaplan GG. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: a network meta-analysis. Gastroenterology. 2015;148:344-54.e5. https:\/\/doi.org\/10.1053\/j.gastro.2014.10.011.","journal-title":"Gastroenterology"},{"key":"817_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/apt.13847","volume":"45","author":"EJ Mao","year":"2017","unstructured":"Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn\u2019s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45:3\u201313. https:\/\/doi.org\/10.1111\/apt.13847.","journal-title":"Aliment Pharmacol Ther"},{"key":"817_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/clep.S150030","volume":"10","author":"R Di Domenicantonio","year":"2018","unstructured":"Di Domenicantonio R, Trotta F, Cascini S, Agabiti N, Kohn A, Gasbarrini A, Davoli M, Addis A. Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. Clin Epidemiol. 2018;10:203\u201313. https:\/\/doi.org\/10.2147\/clep.S150030.","journal-title":"Clin Epidemiol"},{"key":"817_CR22","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s10620-017-4874-6","volume":"63","author":"A Benmassaoud","year":"2018","unstructured":"Benmassaoud A, Al-Taweel T, Sasson MS, Moza D, Strohl M, Kopylov U, Paradis-Surprenant L, Almaimani M, Bitton A, Afif W, Lakatos PL, Bessissow T. Comparative effectiveness of infliximab versus adalimumab in patients with biologic-Na\u00efve Crohn\u2019s disease. Dig Dis Sci. 2018;63:1302\u201310. https:\/\/doi.org\/10.1007\/s10620-017-4874-6.","journal-title":"Dig Dis Sci"},{"key":"817_CR23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1097\/meg.0000000000002087","volume":"33","author":"A Tursi","year":"2021","unstructured":"Tursi A, Mocci G, Lorenzetti R, Allegretta L, Brandimarte G, Cassieri C, Colucci R, De Medici A, Faggiani R, Ferronato A, Fiorella S, Forti G, Franceschi M, Gallina S, Giorgetti G, Grasso G, Larussa T, Luzza F, Penna A, Pica R, Piergallini S, Porciello S, Pranzo G, Rodino S, Scorza S, Sebkova L, Zampaletta C, Elisei W, Picchio M. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. Eur J Gastroenterol Hepatol. 2021;33:670\u20139. https:\/\/doi.org\/10.1097\/meg.0000000000002087.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"817_CR24","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1002\/ibd.22873","volume":"18","author":"DA Sussman","year":"2012","unstructured":"Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, M, TA,. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis. 2012;18:2043\u201355. https:\/\/doi.org\/10.1002\/ibd.22873.","journal-title":"Inflamm Bowel Dis"},{"key":"817_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"817_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312. https:\/\/doi.org\/10.1016\/0197-2456(95)00134-4.","journal-title":"Control Clin Trials"},{"key":"817_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/s0140-6736(98)01085-x","volume":"352","author":"D Moher","year":"1998","unstructured":"Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609\u201313. https:\/\/doi.org\/10.1016\/s0140-6736(98)01085-x.","journal-title":"Lancet"},{"key":"817_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"817_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"key":"817_CR30","unstructured":"Alderson P, Green S, Deeks J, Higgins J. 2002 Cochrane collaboration open learning materials for reviewers. The Cochrane Collaboration\u00ae"},{"key":"817_CR31","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-94. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00136.","journal-title":"Ann Intern Med"},{"key":"817_CR32","doi-asserted-by":"publisher","first-page":"175628482093896","DOI":"10.1177\/1756284820938960","volume":"13","author":"B Chen","year":"2020","unstructured":"Chen B, Gao X, Zhong J, Ren J, Zhu X, Liu Z, Wu K, Kalabic J, Yu Z, Huang B, Kwatra N, Doan T, Robinson AM, Chen MH. Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn\u2019s disease: results from a randomized trial. Therap Adv Gastroenterol. 2020;13:1756284820938960. https:\/\/doi.org\/10.1177\/1756284820938960.","journal-title":"Therap Adv Gastroenterol"},{"key":"817_CR33","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D\u2019Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829\u201338. https:\/\/doi.org\/10.7326\/0003-4819-146-12-200706190-00159.","journal-title":"Ann Intern Med"},{"key":"817_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","volume":"6","author":"M Watanabe","year":"2012","unstructured":"Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, Camez A. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn\u2019s disease. J Crohns Colitis. 2012;6:160\u201373. https:\/\/doi.org\/10.1016\/j.crohns.2011.07.013.","journal-title":"J Crohns Colitis"},{"key":"817_CR35","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/meg.0000000000001917","volume":"33","author":"GB Nigam","year":"2021","unstructured":"Nigam GB, Bhandare AP, Antoniou GA, Limdi JK. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol. 2021;33:346\u201357. https:\/\/doi.org\/10.1097\/meg.0000000000001917.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"817_CR36","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/meg.0000000000001673","volume":"32","author":"E Ozkan","year":"2020","unstructured":"Ozkan E, Basaranoglu M. Recurrent \u201cgloves and socks\u201d distribution with bullous eruptions after adalimumab and infliximab treatment in a patient with Crohn\u2019s disease. Eur J Gastroenterol Hepatol. 2020;32:666\u20137. https:\/\/doi.org\/10.1097\/meg.0000000000001673.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"817_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"817_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0000000000002250","author":"T Greener","year":"2021","unstructured":"Greener T, Boland K, Milgrom R, Ben-Bassat O, Steinhart AH, Silverberg MS, Narula N. Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn\u2019s disease patients. Eur J Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1097\/meg.0000000000002250.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"817_CR39","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","volume":"145","author":"JP Terdiman","year":"2013","unstructured":"Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American Gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-\u03b1 biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease. Gastroenterology. 2013;145:1459\u201363. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.047.","journal-title":"Gastroenterology"},{"key":"817_CR40","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5\u00a0years of follow-up in the TREAT\u2122 registry. Am J Gastroenterol. 2012;107:1409\u201322. https:\/\/doi.org\/10.1038\/ajg.2012.218.","journal-title":"Am J Gastroenterol"},{"key":"817_CR41","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/ajg.2013.138","volume":"108","author":"AC Ford","year":"2013","unstructured":"Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268\u201376. https:\/\/doi.org\/10.1038\/ajg.2013.138.","journal-title":"Am J Gastroenterol"},{"key":"817_CR42","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","volume":"142","author":"P Rutgeerts","year":"2012","unstructured":"Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D\u2019Haens G. Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102-11.e2. https:\/\/doi.org\/10.1053\/j.gastro.2012.01.035.","journal-title":"Gastroenterology"},{"key":"817_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/meg.0000000000001561","volume":"32","author":"N Plevris","year":"2020","unstructured":"Plevris N, Jenkinson PW, Arnott ID, Jones GR, Lees CW. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn\u2019s disease. Eur J Gastroenterol Hepatol. 2020;32:32\u20137. https:\/\/doi.org\/10.1097\/meg.0000000000001561.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"817_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/apt.14420","volume":"47","author":"JF Colombel","year":"2018","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H. Long-term safety of adalimumab in clinical trials in adult patients with Crohn\u2019s disease or ulcerative colitis. Aliment Pharmacol Ther. 2018;47:219\u201328. https:\/\/doi.org\/10.1111\/apt.14420.","journal-title":"Aliment Pharmacol Ther"},{"key":"817_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012878.pub2","author":"M Abbass","year":"2019","unstructured":"Abbass M, Cepek J, Parker CE, Nguyen TM, MacDonald JK, Feagan BG, Khanna R, Jairath V. Adalimumab for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2019. https:\/\/doi.org\/10.1002\/14651858.CD012878.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"817_CR46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1751-2980.2011.00493.x","volume":"12","author":"ML Huang","year":"2011","unstructured":"Huang ML, Ran ZH, Shen J, Li XB, Xu XT, Xiao SD. Efficacy and safety of adalimumab in Crohn\u2019s disease: meta-analysis of placebo-controlled trials. J Dig Dis. 2011;12:165\u201372. https:\/\/doi.org\/10.1111\/j.1751-2980.2011.00493.x.","journal-title":"J Dig Dis"},{"key":"817_CR47","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00228-014-1702-1","volume":"70","author":"YN Song","year":"2014","unstructured":"Song YN, Zheng P, Xiao JH, Lu ZJ. Efficacy and safety of adalimumab for the Crohn\u2019s disease: a systematic review and meta-analysis of published randomized placebo-controlled trials. Eur J Clin Pharmacol. 2014;70:907\u201314. https:\/\/doi.org\/10.1007\/s00228-014-1702-1.","journal-title":"Eur J Clin Pharmacol"},{"key":"817_CR48","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/s2468-1253(21)00312-5","volume":"6","author":"S Singh","year":"2021","unstructured":"Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:1002\u201314. https:\/\/doi.org\/10.1016\/s2468-1253(21)00312-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"817_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365. https:\/\/doi.org\/10.1053\/j.gastro.2006.11.041.","journal-title":"Gastroenterology"},{"key":"817_CR50","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial. Gut. 2007;56:1232\u20139. https:\/\/doi.org\/10.1136\/gut.2006.106781.","journal-title":"Gut"},{"key":"817_CR51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/gutjnl-2013-304488","volume":"63","author":"P Dewint","year":"2014","unstructured":"Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, Ponsioen CI, van Dullemen HM, Russel M, van Bodegraven AA, van der Woude CJ. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn\u2019s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2013-304488.","journal-title":"Gut"},{"key":"817_CR52","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2020.00025","author":"T Hisamatsu","year":"2020","unstructured":"Hisamatsu T, Suzuki Y, Kobayashi M, Hagiwara T, Kawaberi T, Ogata H, Matsui T, Watanabe M, Hibi T. Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn\u2019s disease: 3-year results from a real-world study. Intest Res. 2020. https:\/\/doi.org\/10.5217\/ir.2020.00025.","journal-title":"Intest Res"},{"key":"817_CR53","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/ecco-jcc\/jjy223","volume":"13","author":"R Panaccione","year":"2019","unstructured":"Panaccione R, L\u00f6fberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF. Efficacy and Safety of Adalimumab by disease duration: analysis of pooled data from Crohn\u2019s disease studies. J Crohns Colitis. 2019;13:725\u201334. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy223.","journal-title":"J Crohns Colitis"},{"key":"817_CR54","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/meg.0000000000000296","volume":"27","author":"A Echarri","year":"2015","unstructured":"Echarri A, Ollero V, Barreiro-de Acosta M, Fern\u00e1ndez-Villaverde A, Hern\u00e1ndez V, Lorenzo A, Pereira S, Carpio D, Castro J. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn\u2019s disease: predictors of efficacy in clinical practice. Eur J Gastroenterol Hepatol. 2015;27:430\u20135. https:\/\/doi.org\/10.1097\/meg.0000000000000296.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"817_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/ceg.S263685","volume":"13","author":"RF Beraldo","year":"2020","unstructured":"Beraldo RF, Marcondes MB, Baima JP, Barros JR, Ramdeen M, Saad-Hossne R, Sassaki LY. Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with Crohn\u2019s disease? Clin Exp Gastroenterol. 2020;13:293\u20138. https:\/\/doi.org\/10.2147\/ceg.S263685.","journal-title":"Clin Exp Gastroenterol"},{"key":"817_CR56","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000506074","volume":"236","author":"L Salvador-Rodriguez","year":"2020","unstructured":"Salvador-Rodriguez L, Montero-V\u00edlchez T, Arias-Santiago S, Molina-Leyva A. Paradoxical hidradenitis suppurativa in patients receiving TNF-\u03b1 inhibitors: case series, systematic review, and case meta-analysis. Dermatology. 2020;236:307\u201313. https:\/\/doi.org\/10.1159\/000506074.","journal-title":"Dermatology"},{"key":"817_CR57","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1136\/gutjnl-2020-321240","volume":"69","author":"A Tursi","year":"2020","unstructured":"Tursi A, Angarano G, Monno L, Saracino A, Signorile F, Ricciardi A, Papa A. COVID-19 infection in Crohn\u2019s disease under treatment with adalimumab. Gut. 2020;69:1364\u20135. https:\/\/doi.org\/10.1136\/gutjnl-2020-321240.","journal-title":"Gut"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00817-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00817-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00817-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T23:26:54Z","timestamp":1664494014000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00817-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00817-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All the authors agree to publish this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}